Correlation Study on Serum PCSK9 and Carotid Atherosclerosis in Patients with Primary Hypertension
YANG Wei, TENG Lin, DING Jia-wang, et al
Department of Cardiovascular Disease, Yichang Central People's Hospital, the First College of Clinical Medcial Science, the Three Gorges University, Yichang 443003,China
Abstract：【Objective】 To investigate the correlation between serum proprotein convertase subtilisin/kexin type 9 (PCSK9) and carotid atherosclerosis in primary hypertension patients. 【Methods】 320 primary hypertension patients were divided into non-carotid atherosclerosis (NCAS) group and carotid atherosclerosis (CAS) group according to CIMT. Body mass index(BMI), blood pressure, blood glucose, blood lipid and serum PCSK9 were measured. logistic multiple regression was used to analyze the correlative factors of serum PCSK-9 level and CIMT .【Results】 The levels of serum PCSK-9 in the CAS group (366.9±72.3) mg/L were significantly higher than that of the NCAS group (280.2±61.4) mg/L. The difference was statistically significant (P<0.05). Logistic multivariate regression analysis revealed that serum PCSK9 was the independent risk factor of carotid atherosclerosis in primary hypertension patients.【Conclusion】The level of serum PCSK-9 is positively correlated with CIMT in patients with primary hypertension, it could be an independent risk factor for atherosclerotic disease.
杨伟,滕林,丁家望,李松,杨简,吴辉,杨俊通. 原发性高血压患者血清前蛋白转化酶枯草溶菌素9与颈动脉粥样硬化的相关性研究[J]. 医学临床研究, 2016, 33(11): 2116-2118.
YANG Wei, TENG Lin, DING Jia-wang, et al. Correlation Study on Serum PCSK9 and Carotid Atherosclerosis in Patients with Primary Hypertension. JOURNAL OF CLINICAL RESEARCH, 2016, 33(11): 2116-2118.
[1] Wang J, Zhang L, Wang F,et al. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey[J].Am J Hypertens,2014, 27(11): 1355-1361. [2] Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients[J].J Hypertens,2011, 29(7): 1253-1269. [3] Bergeron N, Phan B A P, Ding Y, et al. Proprotein Convertase Subtilisin/Kexin type 9 inhibition a new therapeutic mechanism for reducing cardiovascular disease risk[J].Circulation,2015, 132(17): 1648-1666. [4] Urban D, P?ss J, B?hm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis[J].J Am Coll Cardiol,2013,62(16):1401-1408. [5] 张祥芳. 新诊断 2 型糖尿病患者血清 25 羟维生素 D 与颈动脉粥样硬化的相关性研究[J].医学临床研究, 2015, 32(3): 557-559. [6] Xiong H, Wu D, Tian X, et al. The relationship between the 24h blood pressure variability and carotid intima-media thickness:a compared study[J].Comput Math Methods Med,2014,11(2): 303-312. [7] Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment a meta-analysis of randomized controlled trials[J].Stroke,2006, 37(7): 1933-1940. [8] 李娇, 李广平. 前蛋白转化酶枯草溶菌素 9 在动脉粥样硬化中的作用[J].临床荟萃, 2015 (3): 341-344. [9] 胥雪莲, 何川. 前蛋白转化酶枯草溶菌素 9 与动脉粥样硬化[J].心血管病学进展, 2016, 37(1): 50-53. [10] Leander K, Mlarstig A, van't Hooft F M, et al. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors[J].Circulation,2016, 133(13): 1230-1239. [11] Robinson JG,Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1489-1499. [12] Sabatine MS, Giugliano RP, Wiviott SD,et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1500-1509.
2016, Vol. 33 
